[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 3061
1. Kathiresan G, Clement RF, Sankaranarayanan MT: Dyspnea in lung cancer patients: a systematic review. Lung Cancer (Auckl); 2010;1:141-150

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dyspnea in lung cancer patients: a systematic review.
  • Dyspnea is a common and distressing symptom experienced by 19%-51% of patients with advanced cancer.
  • While the prevalence of dyspnea has been reported to be as frequent as pain in people with lung cancer, less attention has been paid to the distress associated with dyspnea.
  • This review of the literature was undertaken to investigate how dyspnea has been assessed and whether breathlessness in people with lung cancer is distressing.
  • Overall, the studies report a high prevalence of dyspnea in lung cancer patients, with subjects experiencing a moderate level of dyspnea intensity and interference with activities of daily living.
  • However, taking into account the prevalence, intensity, and distress of dyspnea, the general consensus appears to be that the experience of dyspnea in people with lung cancer is common, with varying degrees of intensity, but involves considerable unpleasantness.
  • Thus, if dyspnea and pain are both distressing sensations for people with lung cancer, this has potential implications for both clinical and academic areas with regards to both management strategies and further research.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Nurs. 2007 Mar-Apr;30(2):E1-8 [17413770.001]
  • [Cites] J Pain Symptom Manage. 2002 Jun;23(6):490-500 [12067773.001]
  • [Cites] J Pain Symptom Manage. 2004 Aug;28(2):133-9 [15276194.001]
  • [Cites] J Pain Symptom Manage. 2001 Apr;21(4):323-9 [11312047.001]
  • [Cites] J Pain Symptom Manage. 2001 Feb;21(2):95-102 [11226761.001]
  • [Cites] Cancer Nurs. 2000 Apr;23(2):82-90 [10763278.001]
  • [Cites] J Pain Symptom Manage. 2005 Jun;29(6):572-83 [15963866.001]
  • [Cites] Cancer. 2005 Nov 1;104(9):2013-21 [16178002.001]
  • [Cites] Cancer Nurs. 2002 Aug;25(4):309-17 [12181499.001]
  • [Cites] J Pain Symptom Manage. 2002 May;23(5):417-23 [12007759.001]
  • [Cites] J Pain Symptom Manage. 2002 Jun;23(6):484-9 [12067772.001]
  • [Cites] J Clin Oncol. 2007 Dec 1;25(34):5381-9 [18048819.001]
  • [Cites] Eur J Cancer Care (Engl). 1999 Mar;8(1):37-43 [10362952.001]
  • [Cites] Acta Oncol. 2000;39(8):949-58 [11207002.001]
  • [Cites] Anticancer Res. 2001 Nov-Dec;21(6A):4077-82 [11911295.001]
  • [Cites] J Palliat Med. 2001 Summer;4(2):157-65 [11441624.001]
  • [Cites] Cancer. 2002 Sep 1;95(5):1085-93 [12209695.001]
  • [Cites] Oncol Nurs Forum. 1986 Sep-Oct;13(5):19-24 [3638715.001]
  • [Cites] J Pain Symptom Manage. 1997 Sep;14(3):136-46 [9291700.001]
  • [Cites] Image J Nurs Sch. 1995 Spring;27(1):35-41 [7721308.001]
  • [Cites] J Pain Symptom Manage. 2007 Oct;34(4):370-9 [17616335.001]
  • [Cites] Chest. 2003 Jan;123(1 Suppl):97S-104S [12527569.001]
  • [Cites] Soc Sci Med. 1983;17(7):431-8 [6867788.001]
  • [Cites] Psychooncology. 2002 Jan-Feb;11(1):12-22 [11835589.001]
  • [Cites] J Pain Symptom Manage. 2000 Apr;19(4):249-56 [10799791.001]
  • [Cites] Qual Life Res. 2007 Dec;16(10):1635-45 [17922222.001]
  • [Cites] Hematol Oncol Clin North Am. 2005 Dec;19(6):1175-90, viii [16325130.001]
  • [Cites] Br J Cancer. 1995 Mar;71(3):633-6 [7533520.001]
  • [Cites] J Pain Symptom Manage. 2002 Mar;23(3):182-9 [11888716.001]
  • [Cites] Cancer Pract. 1993 May-Jun;1(1):21-8 [8324526.001]
  • [Cites] Heart Lung. 1997 Jan-Feb;26(1):23-30 [9013218.001]
  • [Cites] Eur J Oncol Nurs. 2005 Dec;9(4):325-33 [16298550.001]
  • (PMID = 28210113.001).
  • [Journal-full-title] Lung Cancer (Auckland, N.Z.)
  • [ISO-abbreviation] Lung Cancer (Auckl)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Keywords] NOTNLM ; breathlessness / distress / fatigue / neoplasm / scale
  •  go-up   go-down


2. Moreno Luna LE, Kipp B, Halling KC, Sebo TJ, Kremers WK, Roberts LR, Barr Fritcher EG, Levy MJ, Gores GJ: Advanced cytologic techniques for the detection of malignant pancreatobiliary strictures. Gastroenterology; 2006 Oct;131(4):1064-72
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced cytologic techniques for the detection of malignant pancreatobiliary strictures.
  • BACKGROUND & AIMS: Two advanced cytologic techniques for detecting aneuploidy-digital image analysis (DIA) and fluorescence in situ hybridization (FISH)-have recently been developed to help identify malignant pancreatobiliary strictures.
  • The aim of this study was to assess the clinical utility of cytology, DIA, and FISH for the identification of malignant pancreatobiliary strictures.
  • CONCLUSIONS: These findings suggest that FISH and DIA increase the sensitivity for the diagnosis of malignant pancreatobiliary tract strictures over that obtained by conventional cytology while maintaining an acceptable specificity.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Mol Cell Biol. 2004 Sep;5(9):752-62 [15340382.001]
  • [Cites] J Am Med Assoc. 1949 Sep 24;141(4):254-7 [18139551.001]
  • [Cites] Mayo Clin Proc. 1995 Jan;70(1):81-2 [7528866.001]
  • [Cites] Am J Gastroenterol. 1995 May;90(5):722-6 [7733076.001]
  • [Cites] Gastrointest Endosc. 1999 Mar;49(3 Pt 1):322-7 [10049415.001]
  • [Cites] J Urol. 2005 Feb;173(2):401-4 [15643180.001]
  • [Cites] World J Gastroenterol. 2005 Sep 7;11(33):5209-12 [16127754.001]
  • [Cites] Clin Cancer Res. 2005 Sep 1;11(17):6177-85 [16144918.001]
  • [Cites] Rheumatol Int. 2005 Oct;25(8):571-5 [15221280.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Jan 1;116(1):6-9 [10616524.001]
  • [Cites] Am J Gastroenterol. 2000 Jan;95(1):204-7 [10638584.001]
  • [Cites] Br J Cancer. 2000 Apr;82(8):1407-14 [10780519.001]
  • [Cites] Hum Pathol. 2000 Jul;31(7):854-9 [10923924.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Aug;121(1):61-6 [10958943.001]
  • [Cites] J Hepatol. 2000 Dec;33(6):873-7 [11131447.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Mar;30(3):310-5 [11170291.001]
  • [Cites] Int J Cancer. 2001 Jun 15;92(6):816-23 [11351301.001]
  • [Cites] J Clin Pathol. 2001 Jun;54(6):449-55 [11376018.001]
  • [Cites] Gastrointest Endosc. 2002 Oct;56(4):552-61 [12297773.001]
  • [Cites] Diagn Cytopathol. 2003 Apr;28(4):196-204 [12672095.001]
  • [Cites] Cancer Genet Cytogenet. 2003 May;143(1):89-91 [12742162.001]
  • [Cites] Gastrointest Endosc. 2003 Aug;58(2):176-82 [12872082.001]
  • [Cites] J Gastroenterol Hepatol. 2003 Nov;18(11):1287-92 [14535986.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Mar;2(3):214-9 [15017605.001]
  • [Cites] Am J Gastroenterol. 2004 Sep;99(9):1675-81 [15330900.001]
  • [Cites] Am J Gastroenterol. 2004 Sep;99(9):1684-9 [15330902.001]
  • [Cites] Gastrointest Endosc. 2004 Sep;60(3):390-6 [15332029.001]
  • [Cites] Acta Cytol. 2005 Sep-Oct;49(5):471-6 [16334021.001]
  • [Cites] Mayo Clin Proc. 1993 Sep;68(9):874-9 [8396700.001]
  • (PMID = 17030177.001).
  • [ISSN] 0016-5085
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK059427; United States / PHS HHS / / NIH 59427
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  • [Other-IDs] NLM/ NIHMS14109; NLM/ PMC1769444
  •  go-up   go-down


3. Mittal R, Al Awadi S, Sahar O, Behbehani AM: Ewing's sarcoma as second malignant neoplasm after retinoblastoma: a case report. Med Princ Pract; 2008;17(1):84-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ewing's sarcoma as second malignant neoplasm after retinoblastoma: a case report.
  • He was fully investigated and found to have locally advanced RB with bone marrow involvement (Reese-Ellsworth stage IVA).
  • CONCLUSIONS: This case confirms the increased risk of a second malignant neoplasm (SMN) in children with hereditary RB.

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • Genetic Alliance. consumer health - Retinoblastoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 S. Karger AG, Basel.
  • (PMID = 18059108.001).
  • [ISSN] 1423-0151
  • [Journal-full-title] Medical principles and practice : international journal of the Kuwait University, Health Science Centre
  • [ISO-abbreviation] Med Princ Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


Advertisement
4. Yajima N, Yamanaka R, Mine T, Tsuchiya N, Homma J, Sano M, Kuramoto T, Obata Y, Komatsu N, Arima Y, Yamada A, Shigemori M, Itoh K, Tanaka R: Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma. Clin Cancer Res; 2005 Aug 15;11(16):5900-11
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma.
  • PURPOSE: The primary goal of this phase I study was to assess the safety and immunologic responses of personalized peptide vaccination for patients with advanced malignant glioma.
  • EXPERIMENTAL DESIGN: Twenty-five patients with advanced malignant glioma (8 grade 3 and 17 grade 4 gliomas) were evaluated in a phase I clinical study of a personalized peptide vaccination.
  • CONCLUSIONS: Personalized peptide vaccinations were recommended for the further clinical study to malignant glioma patients.
  • [MeSH-major] Brain Neoplasms / immunology. Cancer Vaccines / immunology. Glioma / immunology. Peptides / immunology
  • [MeSH-minor] Adult. Aged. Antigens, Neoplasm / genetics. Female. Gene Expression Regulation, Neoplastic / immunology. HLA-A Antigens / immunology. HLA-A2 Antigen / immunology. HLA-A24 Antigen. Humans. Immunoglobulin G / blood. Immunoglobulin G / cerebrospinal fluid. Leukocytes, Mononuclear / immunology. Male. Middle Aged. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Survival Analysis. T-Lymphocytes, Cytotoxic / immunology. Treatment Outcome

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Cancer Res. 2005 Aug 15;11(16):5663-4 [16115899.001]
  • (PMID = 16115932.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Cancer Vaccines; 0 / HLA-A Antigens; 0 / HLA-A2 Antigen; 0 / HLA-A24 Antigen; 0 / Immunoglobulin G; 0 / Peptides; 0 / RNA, Messenger
  •  go-up   go-down


5. Chi DS, Phaëton R, Miner TJ, Kardos SV, Diaz JP, Leitao MM Jr, Gardner G, Huh J, Tew WP, Konner JA, Sonoda Y, Abu-Rustum NR, Barakat RR, Jaques DP: A prospective outcomes analysis of palliative procedures performed for malignant intestinal obstruction due to recurrent ovarian cancer. Oncologist; 2009 Aug;14(8):835-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective outcomes analysis of palliative procedures performed for malignant intestinal obstruction due to recurrent ovarian cancer.
  • OBJECTIVE: To obtain prospective outcomes data on patients (pts) undergoing palliative operative or endoscopic procedures for malignant bowel obstruction due to recurrent ovarian cancer.
  • METHODS: An institutional study was conducted from July 2002 to July 2003 to prospectively identify pts who underwent an operative or endoscopic procedure to palliate the symptoms of advanced cancer.
  • This report focuses on pts with malignant bowel obstruction due to recurrent ovarian cancer.
  • RESULTS: Palliative interventions were performed on 74 gynecologic oncology pts during the study period, of which 26 (35%) were for malignant GI obstruction due to recurrent ovarian cancer.
  • CONCLUSION: Patients with malignant bowel obstructions due to recurrent ovarian cancer have a high likelihood of experiencing relief of symptoms with palliative procedures.
  • [MeSH-major] Intestinal Obstruction / surgery. Neoplasm Recurrence, Local / complications. Ovarian Neoplasms / complications. Palliative Care / methods


6. Shang E, Weiss C, Post S, Kaehler G: Retraction: The Influence of Early Supplementation of Parenteral Nutrition on Quality of Life and Body Composition in Patients With Advanced Cancer. JPEN J Parenter Enteral Nutr; 2006;30(3):222-230

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retraction: The Influence of Early Supplementation of Parenteral Nutrition on Quality of Life and Body Composition in Patients With Advanced Cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [RetractionOf] JPEN J Parenter Enteral Nutr. 2006 May-Jun;30(3):222-30 [16639069.001]
  • (PMID = 28052743.001).
  • [ISSN] 0148-6071
  • [Journal-full-title] JPEN. Journal of parenteral and enteral nutrition
  • [ISO-abbreviation] JPEN J Parenter Enteral Nutr
  • [Language] eng
  • [Publication-type] Journal Article; Retraction of Publication
  • [Publication-country] United States
  •  go-up   go-down


7. Vogt PM, Jokuszies A: [Advanced malignant soft tissue tumors: plastic reconstructive options for palliative treatment]. Chirurg; 2010 Dec;81(12):1108-14
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Advanced malignant soft tissue tumors: plastic reconstructive options for palliative treatment].
  • Plastic and reconstructive procedures for the oncological treatment of malignant tumors in the head and neck region, trunk and extremities are primarily curative.
  • Less is known about the treatment options of plastic surgery in patients with locally advanced or incurable tumors.
  • A plethora of symptoms drastically restricts the quality of life in patients with advanced cancer.
  • [MeSH-minor] Forecasting. Germany. Humans. Neoplasm Invasiveness. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann R Coll Surg Engl. 1989 Nov;71(6):349-53 [2481422.001]
  • [Cites] Anaesth Intensive Care. 2002 Oct;30(5):633-40 [12413266.001]
  • [Cites] Plast Reconstr Surg. 1988 Dec;82(6):937-52 [3200957.001]
  • [Cites] Langenbecks Arch Chir. 1986;369:447-50 [2433560.001]
  • [Cites] Rev Chir Orthop Reparatrice Appar Mot. 1989;75(1):1-10 [2734462.001]
  • [Cites] Ther Umsch. 2001 Jul;58(7):435-41 [11508112.001]
  • [Cites] Zentralbl Chir. 2006 Dec;131(6):499-505 [17206570.001]
  • [Cites] Clin Orthop Relat Res. 2003 Oct;(415):248-53 [14612653.001]
  • [Cites] Ann Intern Med. 2008 Jan 15;148(2):141-6 [18195338.001]
  • [Cites] Minerva Chir. 1989 Oct 15;44(19):2049-57 [2694014.001]
  • [Cites] Zentralbl Gynakol. 2005 Dec;127(6):407-11 [16341986.001]
  • [Cites] Palliat Med. 2007 Jul;21(5):417-23 [17901101.001]
  • [Cites] Strahlenther Onkol. 2005 Feb;181(2):124-30 [15702301.001]
  • (PMID = 19949764.001).
  • [ISSN] 1433-0385
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


8. Rojas-Espaillat LA, Rose PG: Management of locally advanced cervical cancer. Curr Opin Oncol; 2005 Sep;17(5):485-92
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of locally advanced cervical cancer.
  • PURPOSE OF REVIEW: Cervical cancer is a significant global public health problem.
  • In underdeveloped countries where screening programs are not widely available and in underserved populations in developed countries, women commonly present with locally advanced disease that is not curable by any extent of radical hysterectomy.
  • This review will critically evaluate the evidence supporting the available treatment modalities for locally advanced cancer of the uterine cervix.
  • RECENT FINDINGS: Concurrent cisplatin-based chemotherapy and radiation have demonstrated significant survival improvement for patients with locally advanced cervical cancer.
  • Advances in imaging and radiotherapy technologies, the inclusion of newer agents to the chemoradiation regimens, the use of new hypoxic cell radiosensitizers and monoclonal antibodies that inhibit cell growth, with consequent increase in malignant cell kill fractions, are some of the new therapeutic options that may be used to improve the survival of these patients.
  • SUMMARY: Continued improvement in understanding the natural history of cervical cancer, the limitations of the current staging system, and these newer therapeutic options will increase the efficacy of chemoradiation and improved the survival of these patients.
  • [MeSH-minor] Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Hyperthermia, Induced. Neoadjuvant Therapy. Neoplasm Staging. Prognosis. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16093801.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 74
  •  go-up   go-down


9. Grocott P: Care of patients with fungating malignant wounds. Nurs Stand; 2007 Feb 21-27;21(24):57-8, 60, 62 passim
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Care of patients with fungating malignant wounds.
  • Any nurse who has cared for a patient with a fungating malignant wound will know that this is a challenging aspect of the care provided to patients with advanced cancer.
  • This is an under-researched area of clinical care and the literature that guides malignant wound care is drawn from disciplines such as oncology, chronic wound care and palliative care.
  • [MeSH-major] Neoplasm Invasiveness. Neoplasms / pathology. Wounds and Injuries / nursing

  • MedlinePlus Health Information. consumer health - Wounds and Injuries.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17345910.001).
  • [ISSN] 0029-6570
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


10. Helyer L, Easson AM: Surgical approaches to malignant bowel obstruction. J Support Oncol; 2008 Mar;6(3):105-13
MedlinePlus Health Information. consumer health - Intestinal Obstruction.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical approaches to malignant bowel obstruction.
  • The management of patients with malignant bowel obstruction (MBO) can be one of the most challenging aspects of advanced cancer care, and as a result, their symptoms are often palliated poorly, especially near the end of life.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Catheterization. Decision Making. Digestive System Surgical Procedures / psychology. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Palliative Care / psychology. Prosthesis Implantation / instrumentation. Stents

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Support Oncol. 2008 Mar;6(3):114-5 [18402301.001]
  • [CommentIn] J Support Oncol. 2008 Mar;6(3):116-7 [18402302.001]
  • (PMID = 18402300.001).
  • [ISSN] 1544-6794
  • [Journal-full-title] The journal of supportive oncology
  • [ISO-abbreviation] J Support Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 62
  •  go-up   go-down


11. Lenormand C, Pelletier C, Goeldel AL, Chenard MP, Grange F: Second malignant neoplasm occurring years after hyperthermic isolated limb perfusion for melanoma. Arch Dermatol; 2010 Mar;146(3):319-21
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second malignant neoplasm occurring years after hyperthermic isolated limb perfusion for melanoma.
  • BACKGROUND: Hyperthermic isolated limb perfusion (HILP) is a useful therapeutic option in patients with locally advanced melanoma of the extremities.
  • Because HILP allows very high doses of cytotoxic agents to be administered without systemic leakage, the theoretical risk of a secondary malignant neoplasm is real, particularly in the treated limb.
  • CONCLUSIONS: Because long-term survivors of regionally advanced melanoma, although rare, do exist, candidates for HILP should be warned of the risk of long-term development of nonmelanoma secondary cancers.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20231505.001).
  • [ISSN] 1538-3652
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Ababneh K, Al-Khateeb T: Aggressive pregnancy tumor mimicking a malignant neoplasm: a case report. J Contemp Dent Pract; 2009;10(6):E072-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive pregnancy tumor mimicking a malignant neoplasm: a case report.
  • AIM: The aim of this report is to present the management of an aggressive, highly proliferative pregnancy tumor with clinical and radiographic characteristics highly suggestive of a malignant neoplasm.
  • Advanced alveolar bone loss also was found beneath the lesion.
  • A malignant process was suspected, and an incisional biopsy revealed a pregnancy tumor.
  • SUMMARY: Pregnancy tumor represents an important differential diagnosis of oral masses and can behave in a very aggressive fashion, mimicking a malignant tumor.

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20020084.001).
  • [ISSN] 1526-3711
  • [Journal-full-title] The journal of contemporary dental practice
  • [ISO-abbreviation] J Contemp Dent Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. McDonald A, Lesage P: Palliative management of pressure ulcers and malignant wounds in patients with advanced illness. J Palliat Med; 2006 Apr;9(2):285-95
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Palliative management of pressure ulcers and malignant wounds in patients with advanced illness.
  • BACKGROUND: Pressure ulcers and malignant wounds are prevalent in populations with advanced illness.
  • OBJECTIVE: This review explores the palliative approach to managing pressure ulcers and malignant wounds in patients with advanced illness.
  • [MeSH-minor] Humans. Neoplasm Metastasis. United States

  • MedlinePlus Health Information. consumer health - Palliative Care.
  • MedlinePlus Health Information. consumer health - Pressure Sores.
  • MedlinePlus Health Information. consumer health - Wounds and Injuries.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16629558.001).
  • [ISSN] 1096-6218
  • [Journal-full-title] Journal of palliative medicine
  • [ISO-abbreviation] J Palliat Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 44
  •  go-up   go-down


14. Pirl WF, Solis J, Temel JS, Admane S, Rosovsky R, Prigerson HG, Greer J: Longitudinal course of suicidal ideation in patients with newly diagnosed thoracic cancers. J Clin Oncol; 2009 May 20;27(15_suppl):9606

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 9606 Background: While cancer itself is associated with elevated suicide rates, thoracic cancers have the highest rates.
  • Previous studies of suicidal ideation (SI) in cancer patients have all been cross-sectional.
  • This study investigates the longitudinal course of SI in newly diagnosed thoracic cancer patients.
  • METHODS: Between 8/7/07-9/16/08, a prospective cohort was recruited from consecutive new patients at a thoracic oncology clinic in an academic cancer center.
  • At initial visit, 254 (68.1%) had known lung cancers, 38 (10.2%) had esophageal cancer.
  • 127 (34.1%) had advanced cancer.
  • Cancer type and stage were not significantly associated.
  • CONCLUSIONS: Newly diagnosed thoracic cancer patients had a 6% SI rate at initial visit, slightly lower than other reports with mixed cancers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963838.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Kamal AH, Swetz KM, Liu H, Ruegg SR, Carey EC, Whitford K, Bock FA, Creagan ET, Moynihan TJ, Kaur JS: Survival trends in palliative care patients with cancer: A Mayo Clinic 5-year review. J Clin Oncol; 2009 May 20;27(15_suppl):9592

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival trends in palliative care patients with cancer: A Mayo Clinic 5-year review.
  • : 9592 Background: Palliative care (PC) is an essential part of the continuum of care for cancer (CA) patients (pts).
  • Cancer is the most common primary diagnosis (47%).
  • This highlights the importance of earlier outpatient palliative care involvement with advanced cancer patients and families.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963727.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Greer J, Temel J, Admane S, Solis J, Lynch T, Pirl W: Code status documentation in the outpatient electronic medical records of patients with metastatic cancer. J Clin Oncol; 2009 May 20;27(15_suppl):9576

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Code status documentation in the outpatient electronic medical records of patients with metastatic cancer.
  • : 9576 Background: Advanced care planning is an essential component of cancer care for patients with incurable malignancies.
  • METHODS: We conducted a retrospective review of outpatient medical records of 2498 patients with metastatic solid tumors seen at an academic cancer center from 10/1/06 through 2/29/08.
  • An electronic database was used to gather information on patient demographics, cancer type, and visits to the cancer center.
  • Independent predictors of having documented code status included cancer type and a greater number of visits to the cancer center.
  • Given the importance of advanced care planning for those with terminal illness, interventions are needed to encourage discussion and documentation of end-of-life care preferences in patients with advanced cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963711.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Rodriguez Garzotto A, Sepulveda J, Cortijo A, Garcia L, Garcia Rodriguez I, Ciruelos E, Rodriguez Antolin A, Cortes-Funes H, Castellano D: Oral vinorelbine as a fixed-weekly schedule in taxanes-refractory advanced HRPC: A single institution experience. J Clin Oncol; 2009 May 20;27(15_suppl):e16084

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral vinorelbine as a fixed-weekly schedule in taxanes-refractory advanced HRPC: A single institution experience.
  • : e16084 Background: Vinorelbine (VRL) has been shown to be active in hormone-refractory prostate cancer (HRPC).
  • Oral formulation of VRL represents a significant advance in the treatment of advanced cancer.
  • RESULTS: Thirty seven pts with progressive HR metastatic prostate cancer were evaluated.
  • CONCLUSIONS: Oral Vinorelbine administered as a fixed-weekly schedule of 60 mg/m2 is a safe regimen in pts with advanced HRPC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963107.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Schrader AJ, Rauer-Bruening S, Olbert PJ, Hegele A, Rustemeier J, Hofmann R: Incidence and long term prognosis of papillary renal cell carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e16020

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e16020 Background: Papillary renal cell carcinoma (pRCC) represents the largest subgroup of non clear-cell kidney cancer.
  • In this study we assessed tumour characteristics and long-term prognosis of patients with pRCC in comparison with conventional clear-cell cancer (ccRCC).
  • However, we observed a trend towards an improved outcome for organ confined (pT1-2) cancer, but a significantly inferior prognosis for locally advanced stage (pT3-4) and/or metastatic papillary tumours at the time of renal surgery.
  • However, applying multivariate analysis including age, sex, and tumour grade, histology could neither be retained as a significant independent prognostic marker in the metastatic setting (p = 0.068, cox regression analysis) nor in a subgroup analysis focussing on patients with advanced cancer (pT3-4 and/or N+/M+; p = 0.064, cox regression analysis).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962984.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Figueroa P Sr, Castro Hernández C, Santibáñez Andrade M, Díaz Romero M, Morales Vázquez F, Gallardo Rincón D, Herrera Montalvo LA: Association between Mad1 G558A and ERCC1 C8092A polymorphisms and response to induction chemotherapy in advanced ovarian carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):5568

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association between Mad1 G558A and ERCC1 C8092A polymorphisms and response to induction chemotherapy in advanced ovarian carcinoma.
  • : 5568 Background: Platinum and taxane remain active drugs in the treatment of ovarian cancer.The polymorphism C8092A of ERCC1 is involved in NER pathway of platinum induced damage DNA and Mad1 G558A with modulation of the chromosomal segregation.
  • METHODS: ERCC1 C8092A and Mad1 G558A polymorphism allelic and genotypic frequency was determined on DNA isolated from blood tumor samples by PCR and specific digestion in 56 patients with cancer of advanced ovary who received induction chemotherapy with 3 courses of paclitaxel 175 mg/m<sup>2</sup> and AUC6 carboplatin every 3 weeks.
  • Allele A for Mad1 is more frequently observed in patients with ovarian carcinoma versus in mexican healthy women (61% vs. 49%) and suggests the possibility that the polymorphism of Mad1 is a marker of risk for ovary cancer (RR = 1, 15, p < 0, 05).
  • CONCLUSIONS: This is the first study in ovary cancer that evaluates predictive value of two SNP, one of them involved in the spindle checkpoint and the other in DNA repair mechanism (NER), suggesting to Mad1 G558A likely risk polymorphism for ovary cancer and response to chemotherapy based on taxanes, which may be a predictive biomarker.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962556.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Kolesar J, Brundage R, Pomplun M, Jiang Z, Schelman W, Alberti D, Holen K, Traynor A, Ivy P, Wilding G: Population pharmacokinetics of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):2508

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Population pharmacokinetics of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in cancer patients.
  • : 2508 Background: 3-Aminopyridine-2-carboxaldehyde thiosemicarbazone (3AP) is an inhibitor of ribonucletoide reductatse with activity in hematological malignancies as well as melanoma and prostate cancer.
  • METHODS: 40 pts with advanced cancer from two phase 1 studies were included in the PK model building.
  • Supported by: U01CA062491 "Early Clinical Trials of Anti-Cancer Agents with Phase I Emphasis" NCI; CTEP TRI Funding 24XS090, and 1ULRR025011 Clinical and Translational Science Award of the National Center for Research Resources, NIH.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961965.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Clive S, Woo MM, Stewart M, Nydam T, Hirawat S, Kagan M: Elucidation of the metabolic and elimination pathways of panobinostat (LBH589) using [&lt;sup&gt;14&lt;/sup&gt;C]-panobinostat. J Clin Oncol; 2009 May 20;27(15_suppl):2549

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Four patients with advanced cancer received a single oral 20 mg dose of [<sup>14</sup>C]-PAN (50 μCi).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961858.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Helft PR, Terry C, Chamness AR, Uhrich MM: Oncology nurses' views of oncologists' prognosis-related communication (PRC). J Clin Oncol; 2009 May 20;27(15_suppl):6602

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 6602 Background: PRC is critical to care, treatment, and decision-making for advanced cancer patients (ACP).
  • METHODS: Mail survey of a random sample of Oncology Nursing Society members with at least one year of experience working with cancer patients (pts).
  • RESULTS: Respondent demographics: median age 49.2, 96.6% female, 88.5% Caucasian, median years (yrs) as an RN 18, median yrs working with cancer patients 12, 69.1% had a BSN or ASN, 34.1% inpt RNs, 38.6% outpt RNs.
  • 25.1% of RNs felt that MDs rarely or never kept them informed about their PRC with pts (frequency positively associated with yrs as an RN, yrs working with cancer pts, education level).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961728.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Stuart RK, Stockerl-Goldstein K, Cooper M, Devetten M, Herzig R, Medeiros B, Schiller G, Wei A, Acton G, Rizzieri D: Randomized phase II trial of the nucleolin targeting aptamer AS1411 combined with high-dose cytarabine in relapsed/refractory acute myeloid leukemia (AML). J Clin Oncol; 2009 May 20;27(15_suppl):7019

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The AS1411 aptamer binds nucleolin on the surface of cancer cells and induces apoptosis.
  • A phase I trial of AS1411 monotherapy in 30 patients with advanced cancer showed objective responses without serious toxicities.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961391.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Mel JR Sr, Ramos M, Cueva J, Castellanos J, Almanza C: Pilot study with pegylated liposomal doxorubicin (PLD) and docetaxel as first-line treatment in patients with metastatic breast cancer (MBC). J Clin Oncol; 2009 May 20;27(15_suppl):e12002

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pilot study with pegylated liposomal doxorubicin (PLD) and docetaxel as first-line treatment in patients with metastatic breast cancer (MBC).
  • METHODS: Pts ≥ 18 years with histologically confirmed breast cancer, advanced disease, PS ≥ 60%, LVEF> 50%, adequate bone marrow, renal and hepatic function were included.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964260.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Lyerly HK, Staley T, Herndon JE 2nd, Coan A, Wheeler JL, Rowe K, Horne B, Abernethy AP: Impact of a psychosocial intervention on performance status and coping. J Clin Oncol; 2009 May 20;27(15_suppl):9611

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 9611 Background: Psychosocial distress is a critical cancer comorbidity; new interventions are needed.
  • METHODS: This prospective, single-arm, pilot study enrolled adult metastatic breast cancer patients with prognosis ≥6 months.
  • RESULTS: Participants (n=50) were: mean age 51.2 years (SD 11.5); 24% non-white; 74% married; 50% did not complete college; the cohort had advanced cancer and short prognosis with 6-month attrition from death, 18%.
  • CONCLUSIONS: Pathfinders had significant positive effect on key psychosocial and QOL outcomes, notably distress and despair, for cancer patients despite advanced disease and worsening symptoms.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963859.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Bottomley A, Coens C, King M, Osoba D, Taphoorn MJ, Reeve B, Ringash J, Schmucker-Von Koch J, Weis J, Quinten C: Is patient self-reporting more accurate than clinician reporting of symptoms for predicting survival in patients with cancer? Meta-analysis of 30 closed EORTC randomized controlled trials. J Clin Oncol; 2009 May 20;27(15_suppl):9597

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is patient self-reporting more accurate than clinician reporting of symptoms for predicting survival in patients with cancer? Meta-analysis of 30 closed EORTC randomized controlled trials.
  • METHODS: Patients with advanced cancer from 30 European Organisation for Research and Treatment of Cancer (EORTC) Randomized Controlled Trials were included in this retrospective pooled analysis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963749.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Karapanagiotou E, Pandha HS, Hall G, Chester J, Melcher A, Coffey M, de Bono J, Gore ME, Nutting CM, Harrington KJ: Phase I/II trial of oncolytic reovirus (Reolysin) in combination with carboplatin/paclitaxel in patients (pts) with advanced solid cancers. J Clin Oncol; 2009 May 20;27(15_suppl):e14519

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I/II trial of oncolytic reovirus (Reolysin) in combination with carboplatin/paclitaxel in patients (pts) with advanced solid cancers.
  • : e14519 Background: Reolysin, a wild type reovirus (Dearing strain), replicates preferentially in Ras-activated cancer cells.
  • RESULTS: 17 heavily pre-treated pts (11 M, median age 55 yrs) with advanced cancer: H&N (10), melanoma (4), peritoneal/endometrial cancer (2), and sarcoma (1) have received 82 cycles of treatment to date; 4 pts are still on study.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963522.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Tahara M, Araki K, Kiyota N, Okano S, Fuse N, Minashi K, Yoshino T, Doi T, Minami H, Ohtsu A: Final results of a phase I trial of chemotherapy combination with docetaxel, cisplatin, and S-1 (TPS) in patients with locally advanced or recurrent metastatic head and neck cancer (HNC). J Clin Oncol; 2009 May 20;27(15_suppl):6021

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Final results of a phase I trial of chemotherapy combination with docetaxel, cisplatin, and S-1 (TPS) in patients with locally advanced or recurrent metastatic head and neck cancer (HNC).
  • : 6021 Background: An oral fluoropyrimidine, S-1, has shown high efficacy against head and neck cancer (HNC), with a response rate of 34%.
  • We investigated the maximum tolerated dose (MTD) of combination therapy with docetaxel, cisplatin and S-1 (TPS) in patients (pts) with locally advanced or recurrent/metastatic HNC.
  • Pts with locally advanced HNC received concurrent chemoradiotherapy after completion of 3 cycles of TPS.
  • Twenty-nine cases were locally advanced cancer and 11 were metastatic cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962417.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Nesselhut J, Lorenzen DR, Marx D, Chang RY, Matthes C, Hildenbrand B, Schneider EM, Nesselhut T: Cellular immune suppression in cancer patients and its implication for dendritic cell therapy. J Clin Oncol; 2009 May 20;27(15_suppl):3028

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cellular immune suppression in cancer patients and its implication for dendritic cell therapy.
  • : 3028 Background: The treatment of human cancer with monocyte-derived dendritic cells (MoDC) is a promising and innovative approach.
  • METHODS: Whole blood from n=100 cancer patients with various tumor types and from n=30 healthy donors were analysed by flow cytometry.
  • RESULTS: We found a significantly higher proportion of CD25<sup>+</sup>/CD39<sup>+</sup> and of CD25<sup>+</sup>/CD127<sup>low</sup> T-helper cells in the blood of cancer patients as compared to healthy donors.
  • This may indicate two different types of T-reg involved in immune suppression in cancer patients.
  • Interestingly, we found a subpopulation of cells within the lymphocyte gate characterized by CD2<sup>high</sup> and CD86 expression in cancer patients with very advanced stage, similar to such normally found in hemaphagocytic lymphohistiocytosis (HLH) patients characterized by exceeding high plasma concentration of IFN-g and IL-10 (Schneider et al. 2002).
  • For the first time, we identified HLH associated cells in advanced cancer patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962066.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Blum D, Hess J, Omlin A, Jurt G, Strasser Abhpm F: Comprehensive cancer cachexia staging and its impact in the outpatient oncology setting: A phase II study. J Clin Oncol; 2009 May 20;27(15_suppl):e20530

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comprehensive cancer cachexia staging and its impact in the outpatient oncology setting: A phase II study.
  • : e20530 Background: Symptom management in advanced cancer is based on appropriate and feasible syndrome staging.
  • METHODS: The multidisciplinary CC (nurse, nutritionist, psycho-oncologist, palliative cancer care physician) applies standardized assessments (Symptom Visual Analogue Scales [VAS, 0=none, 10=severe], 2-day NI diary [% of calculated needs: calories, protein], secondary causes for impaired NI, weight history (2 months WL), Body Mass Index [BMI], C-reactive Protein [mg/dl, normal 8), ERD-VAS, Hospital Anxiety Depression Scale, spirituality [FICA]).
  • Interventions include nutritional counseling, palliative cancer care and psychosocial supportive measures.
  • RESULTS: 58 pts (age 65 years [mean; range: 38, 85]; 28F/30M; cancer types: 24 GI, 13 GU, 12 lung/ENT, 9 other; survival 151 days [7, 776]) had 6.9% WL (-6, 22; 21%<2%), 21 kg/m2 BMI (15, 26), 52 CRP (1, 272; 32% normal), 5.6 anorexia, 1.6 anxiety, 6 HADS-A, 1.3 depression, 9 HADS-D, 68% of NI needs (1466kcal [400, 2700], 47g protein [15, 108]).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960982.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Vigano A, Trutschnigg B, Morais JA, Chaudhury P, Lucar E, Metrakos P, Hassanain M, Molla H, Hornby L, Kilgour RD: Use of the scored Patient-Generated Subjective Global Assessment (PG-SGA) to characterize cachexia in newly diagnosed advanced cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):9574

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of the scored Patient-Generated Subjective Global Assessment (PG-SGA) to characterize cachexia in newly diagnosed advanced cancer patients.
  • : 9574 Background: Our objective was to evaluate whether the scored PGSGA questionnaire in advanced cancer patients (ACP) might relate better then weight loss (WL) alone to the nutritional, functional, biological and quality of life features of cachexia (C) and to some complications related to this syndrome.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963665.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Trivanovic D, Dobrila-Dintinjana R, Mavric Z, Stimac D, Petkovic M: QTc interval in advanced cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):e20658

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] QTc interval in advanced cancer patients.
  • : e20658 Background: The purpose is to identify prognostic factors that may have impact on survival in patients with advanced cancer.
  • METHODS: We retrospectively reviewed the data of patients who had biopsy proven advanced solid cancer disease in stage IV and no history or evidence of any prior cardiac disease.
  • RESULTS: Between 1/01 and 9/05, 143 patients (83 male and 60 female) with advanced cancers were evaluated in our institution.
  • CONCLUSIONS: The results of our study indicate that a prolonged QTc interval (> 440 ms) is an adverse prognostic sign in patients with advanced cancer and without cardiac disease which correlates with increased mortality rates within one year after the diagnosis.
  • Our findings suggest that QTc prolongation may be a good adjunct in risk stratification of patients with advanced cancer who are being considered for aggressive treatment regimens.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961619.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Bastos BR, Diamond J, Hansen R, Gustafson D, Arnott J, Bray M, Sidor C, Messersmith W, Shapiro G: An open-label, dose escalation, safety, and pharmacokinetic study of ENMD-2076 administered orally to patients with advanced cancer. J Clin Oncol; 2009 May 20;27(15_suppl):3520

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An open-label, dose escalation, safety, and pharmacokinetic study of ENMD-2076 administered orally to patients with advanced cancer.
  • This Phase 1 study was designed to evaluate the safety, pharmacokinetics (PK) and preliminary efficacy of ENMD-2076 administered once daily to patients (pts) with advanced cancer.
  • Four ovarian cancer and 2 colon cancer pts have achieved decreases ranging from 11-61% in either CA125 or CEA, respectively (4 are associated with stable disease at Cycle 2 by modified RECIST criteria).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961327.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Fadul NA, Strasser F, Palmer JL, Dalal S, Allo J, Bruera E: The association between autonomic dysfunction and survival in advanced cancer: A preliminary report. J Clin Oncol; 2009 May 20;27(15_suppl):e20534

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The association between autonomic dysfunction and survival in advanced cancer: A preliminary report.
  • : e20534 Background: Autonomic nervous system dysfunction (AD) is a common syndrome in patients with advanced cancer.
  • Based on this available evidence, we hypothesized that autonomic dysfunction is associated with reduced survival in patients with advanced cancer.
  • The objective of this preliminary study was to test the association between AD as measured by the standardized Ewing test and Heart Variability (HRV) measures and survival in patients with advanced cancer.
  • METHODS: We examined the relationship between survival and parameters of AD in male patients with advanced cancer who participated in a prospective study of autonomic dysfunction and hypogonadism.
  • CONCLUSIONS: Autonomic dysfunction is associated with shorter survival in male patients with advanced cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960977.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Adolph MD, Taylor RM, Ross PM, Vaida AM, Moffatt-Bruce SD: Evaluating cancer patient satisfaction before and after daily multidisciplinary care for thoracic surgery inpatients. J Clin Oncol; 2009 May 20;27(15_suppl):9605

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluating cancer patient satisfaction before and after daily multidisciplinary care for thoracic surgery inpatients.
  • : 9605 Background: Significant subpopulations of cancer inpatients in the SUPPORT trial were dissatisfied with their pain control. (Desbiens, Wu et al.
  • 1996) The hospitalized thoracic surgical patient is a person at risk for uncontrolled symptoms and burdens due to advanced cancer at time of presentation.
  • METHODS: This is a retrospective, observational, study of 1188 thoracic surgery patients undergoing elective surgical procedures for lung cancer at an NCI-approved cancer hospital over a 3-year period.
  • Patients with primary and secondary lung cancer, undergoing elective thoracic surgery procedures were evaluated before (n=660, "Period 1") and after (n=528, "Period 2") an 8-month, daily, collaborative multidisciplinary Intervention Period to improve pain control and to facilitate transition for discharge.
  • The collaborative process also identified thoracic surgical patients who needed more complex symptom management and additional support for advanced disease.
  • The collaborative relationship resulted in an increase in referrals to hospice for patients with advanced cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963839.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Rizvi S, Lis J, Boileau K, Garcia-Vargas J: Incidence of thromboembolism in patients receiving vorinostat: Clinical trial and post-marketing data from more than 1,800 patients. J Clin Oncol; 2009 May 20;27(15_suppl):e14547

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e14547 Background: Thromboembolic events (TEEs) occur in approximately 10-15% of advanced cancer patients.
  • Risk factors include cancer therapy and extent and type of malignancy.
  • RESULTS: During the reporting period, data from >1,845 cancer patients who received vorinostat were reviewed.
  • CONCLUSIONS: The incidence rate of TEEs observed in vorinostat studies is similar to reported rates of TEEs for advanced cancer patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963621.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Aboziada MA, El-Sayed MI, Maximous DW, Abdel-Wanis ME, Bakr MM: Feasibility of breast conservation after neoadjuvant taxae-based chemotherapy in locally advanced breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e11627

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Feasibility of breast conservation after neoadjuvant taxae-based chemotherapy in locally advanced breast cancer.
  • : e11627 Background: Neoadjuvant chemotherapy is the standard of care of locally advanced cancer breast.
  • CONCLUSIONS: Breast conservation is feasible in selected cases of locally advanced, non metastatic cancer breast.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961121.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Elser C, Hirte H, Kaizer L, Mackay H, Bindra S, Tinker L, MacAlpine K, Wang L, Sidor C, Oza A: Phase II study of MKC-1 in patients with metastatic or resistant epithelial ovarian cancer or advanced endometrial cancer. J Clin Oncol; 2009 May 20;27(15_suppl):5577

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of MKC-1 in patients with metastatic or resistant epithelial ovarian cancer or advanced endometrial cancer.
  • MKC-1 also reduces pAKT, an attractive target in endometrial cancer due to frequent PTEN mutations.
  • METHODS: The objective of this phase II study is to assess the efficacy of MKC-1 in 2 patient (pt) populations: metastatic or recurrent platinum-resistant ovarian cancer (EOC) and advanced endometrial cancer (EC).
  • 11/4 pts had prior adjuvant CT, 14/10 had prior systemic CT for advanced disease, and 2/6 received prior radiation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962602.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. DeJonge M, Woo MM, Van der Biessen D, Hamberg P, Sharma S, Chen LC, Myke N, Zhao L, Hirawat S, Verweij J: A drug interaction study between ketoconazole and panobinostat (LBH589), an orally active histone deacetylase inhibitor, in patients with advanced cancer. J Clin Oncol; 2009 May 20;27(15_suppl):2501

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A drug interaction study between ketoconazole and panobinostat (LBH589), an orally active histone deacetylase inhibitor, in patients with advanced cancer.
  • METHODS: Patients (pts) with advanced solid tumors or NHL received single-agent PAN at 20 mg on Day 1 and single-agent keto at 400 mg daily on Days 5-9.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961960.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Arkenau H, Evans J, Lokelma M, Roxburgh P, Morisson R, Coffey M, Gill G, Mettinger K, Thompson B, de Bono J: A phase I study of the combination of intravenous Reolysin (REO) and gemcitabine (GEM) in patients (pts) with advanced cancer. J Clin Oncol; 2009 May 20;27(15_suppl):3584

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I study of the combination of intravenous Reolysin (REO) and gemcitabine (GEM) in patients (pts) with advanced cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961749.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Francesconi A, Kotasek D, Burge M, Smith G, Lickliter J: Phase I evaluation of orally-administered CYT997, a novel cytotoxic vascular-disrupting agent, in patients with advanced cancer. J Clin Oncol; 2009 May 20;27(15_suppl):3568

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I evaluation of orally-administered CYT997, a novel cytotoxic vascular-disrupting agent, in patients with advanced cancer.
  • METHODS: CYT997 was administered orally every 2 weeks to patients with advanced solid tumours.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961674.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Cripe LD, Rawl S, Monahan P, Tong Y, Schmidt K, Rand K: Effect of coping styles on the psychological impact of discussing life expectancy for men with advanced cancer. J Clin Oncol; 2009 May 20;27(15_suppl):9615

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of coping styles on the psychological impact of discussing life expectancy for men with advanced cancer.
  • However, appraisal of the cancer threat may enhance coping and improve psychological outcomes for some men with advanced cancer.
  • METHODS: We recruited 81 men with advanced cancer to complete surveys including coping (Mini-MAC), post-traumatic growth (PTGI), psychological outcomes (Hospital Anxiety and Depression Scale).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963867.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Kardinal CG, Sanders JB, Cupper HT: Informed consent: Timely issues from the past. Factors motivating patients with advanced cancer to participate in phase II trials. J Clin Oncol; 2009 May 20;27(15_suppl):e20669

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Informed consent: Timely issues from the past. Factors motivating patients with advanced cancer to participate in phase II trials.
  • METHODS: In 1973 data were collected on the factors motivating 50 consecutive patients with advanced cancer to participate in Phase II trials.
  • CONCLUSIONS: The factors motivating patients with advanced cancer to participate in Phase II trials are complex, but evolve primarily around their personal disease status rather than their understanding of the trial.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961701.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Hirose T, Nishimura K, Fujita K, Adachi M, Sasaki Y, Tanigawara Y: Population pharmacokinetic analysis of S-1 including the CYP2A6 genotype in patients with advanced cancer. J Clin Oncol; 2009 May 20;27(15_suppl):2507

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Population pharmacokinetic analysis of S-1 including the CYP2A6 genotype in patients with advanced cancer.
  • Therefore, we performed a population pharmacokinetic (PPK) analysis of S-1 including the CYP2A6 genotype in Japanese patients with advanced cancer and developed a model describing the disposition kinetics of tegafur, CDHP, and 5-FU after oral administration of S-1.
  • METHODS: Fifty-eight patients with advanced cancer were eligible if they had a performance status of 0 to 3 and had adequate organ function.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961964.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Yennurajalingam S, Urbauer DL, Chacko R, Hui D, Amin YA, Evans AC, Orihuela C, Casper KL, Poulter V, Coldman B, Bruera E: Impact of an outpatient interdisciplinary team (IDT) consultation on symptom clusters in advanced cancer patients seen at a supportive care outpatient clinic (OSC) in a tertiary cancer center. J Clin Oncol; 2009 May 20;27(15_suppl):e20542

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of an outpatient interdisciplinary team (IDT) consultation on symptom clusters in advanced cancer patients seen at a supportive care outpatient clinic (OSC) in a tertiary cancer center.
  • : e20542 Background: Advanced cancer patients develop severe physical and psychosocial symptom clusters.
  • METHODS: 914 consecutive patients with advanced cancer presenting in the OSC from Jan 2003 to Oct 2008 with a complete Edmonton symptom assessment scale at the initial and follow-up visit (median 14 days, range 1-4 wks), and CAGE status (alcohol screening) were reviewed.
  • The most common primary cancer was Lung (19%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961082.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Clarke SJ, Smith JT, Gebbie C, Sweeney C, Olszewski N: A phase I, pharmacokinetic (PK), and preliminary efficacy assessment of ALD518, a humanized anti-IL-6 antibody, in patients with advanced cancer. J Clin Oncol; 2009 May 20;27(15_suppl):3025

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I, pharmacokinetic (PK), and preliminary efficacy assessment of ALD518, a humanized anti-IL-6 antibody, in patients with advanced cancer.
  • : 3025 Background: ALD518 is a humanized anti-IL-6 antibody being developed for the treatment of cancer cachexia and fatigue.
  • METHODS: 9 patients (pts) with advanced cancer, ECOG 0-2, and C-reactive protein (CRP) >10mg/L were enrolled.
  • CONCLUSIONS: ALD518 given to pts with advanced cancer was safe and well tolerated.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962067.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Trice ED, Nilsson ME, Paulk E, DeSanto-Madeya S, Wright AA, Balboni TA, Steiglitz H, Maciejewski PK, Block SD, Prigerson HG: Predictors of aggressive end-of-life care among Hispanic and white advanced cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):9538

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors of aggressive end-of-life care among Hispanic and white advanced cancer patients.
  • : 9538 Background: Some ethnic/racial minority cancer patients (e.g.
  • Nevertheless, few studies have investigated whether Hispanic cancer patients receive more aggressive care than white patients and limited information exists on the predictors of aggressive care among Hispanic patients.
  • The present study examined rates and predictors of aggressive EOL care among Hispanic and white cancer patients.
  • Data were derived from interviews, conducted in English or Spanish, of 292 self-reported Hispanic (N=58) or white (N=234) stage IV cancer patients and their caregivers.
  • RESULTS: Hispanic and white advanced cancer patients were equally likely to receive aggressive EOL care (5.2% and 3.4%, respectively; p=0.878).
  • For both white and Hispanic cancer patients, no patient who reported an EOL discussion or DNR order at baseline received aggressive EOL care.
  • CONCLUSIONS: Given that EOL discussions and DNR orders may prevent aggressive EOL care among Hispanic cancer patients, further efforts to engage Hispanic patients and their caregivers in these activities may reduce aggressive EOL care.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964535.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Prigerson HG, Wright AA, Block SD, Maciejewski PK: Tailoring end-of-life discussions to advanced cancer patients' state of grief. J Clin Oncol; 2009 May 20;27(15_suppl):9500

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tailoring end-of-life discussions to advanced cancer patients' state of grief.
  • Nevertheless, associations between EOL discussions and care received may vary depending on patients' state of grief over their cancer diagnosis.
  • METHODS: Coping with Cancer is an NCI/NIMH-funded, multi-site prospective, longitudinal cohort study of patients with advanced cancer, conducted from September 2002-February 2008.
  • Patients were assessed at baseline on 5 grief states in response to their cancer diagnosis (i.e., numbness, anger, bargaining, depression, and acceptance) and whether an EOL discussion with their physician had occurred.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964453.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Chasen MR, Eades M, Jelowicki M, Amdouni S, Sharma R: The McGill Cancer Nutrition and Rehabilitation Program. J Clin Oncol; 2009 May 20;27(15_suppl):9623

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The McGill Cancer Nutrition and Rehabilitation Program.
  • : 9623 Background: Cancer rehabilitation is a process that assists the individual with cancer to obtain optimal physical, social, psychological, and vocational functioning within the limits created by the disease and treatment.
  • The McGill Cancer Nutrition and Rehabilitation (CNR) program developed as a result of the ever-increasing demand to address the individual cancer patients and their needs, as well as on achieving optimal tumour-related outcomes.
  • METHODS: To assess the effect of an interdisciplinary 8-week rehabilitation program on the functional outcomes of patients with advanced cancer.
  • Sixty-five patients were assessed prior to and following an 8-week interdisciplinary cancer rehabilitation program consisting of medical, nursing, physiotherapy and nutritional interventions.
  • Their cancer diagnoses were: gastro-esophageal (20%), hepatobiliary (19%), breast (17%), hematological (12%), lung, ENT and sarcoma (9% each), colorectal (3%) and CNS lymphoma (2%) There was a significant improvement after an 8-week cancer rehabilitation program in strength (p=.
  • CONCLUSIONS: Preliminary findings suggest that participation in a cancer rehabilitation program ameliorates symptoms and global distress resulting in an increase in physical activities.
  • We can conclude that participation in the Cancer Rehabilitation Program is beneficial.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963902.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Jung G, Knight D, Moadel A, Desai K, Chaudhary I, Gajavelli S, Ghalib MH, Mani S, Goel S: Assessment of quality of life using FACT-G survey in a phase I trial in cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):e20709

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of quality of life using FACT-G survey in a phase I trial in cancer patients.
  • However, there is paucity of evaluation of QoL in patients with advanced cancer participating in Phase I clinical trials.
  • RESULTS: Forty-one of 47 patients with advanced solid tumors who participated in the clinical trial completed FACT-G surveys.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961984.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Drevs J, Lohrmann R, Niazi F, Scheele J, Diergarten K: Phase II/III study of Auron Misheil Therapy (AMT) versus placebo to evaluate clinical benefit response (CBR) in patients with advanced solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):e20696

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II/III study of Auron Misheil Therapy (AMT) versus placebo to evaluate clinical benefit response (CBR) in patients with advanced solid tumors.
  • : e20696 Background: CBR is used as clinical trial endpoint in patients (pts) with advanced cancers.
  • The multicenter randomized double blind phase III study AMT/P2CA/001 compares CBR efficacy and safety of AMT with placebo in patients with advanced solid tumors.
  • METHODS: Pts with inoperable advanced disease refractory to standard therapy or for which no standard therapy existed were included..
  • The general adverse event profile (related and not related events) reflects the advanced cancer disease of the patients, and no relevant differences were observed between the AMT-groups and the Placebo-group.
  • CONCLUSIONS: This study shows that CBR can be achieved with AMT after 2 respectively 6 weeks of treatment even in patients with advanced solid tumors and a clinically relevant number of patients seem to have a benefit from the study treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961748.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Fêde AB, da Costa Miranda V, Martins FD, Magalhães NP, Schaffhausser HL, Riechelmann RP, Del Giglio A: Doctor, how long? J Clin Oncol; 2009 May 20;27(15_suppl):e20653

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e20653 Background: In practice it is common to start terminal sedation for patients with advanced cancer who develop physical discomfort not amenable to be treated by other means.
  • We aimed at quantifying the average survival time of terminal cancer patients once sedation was started until death and identify potential variables that may influence their survival time on sedation.
  • METHODS: This is a retrospective cohort analysis of all consecutive terminal cancer patients who died after starting terminal sedation at public tertiary brazilian Hospital during 2 years (January 2005 to January 2007).
  • RESULTS: 532 cancer patients died in Hospital Estadual Mário Covas during this period and 181 out of them who received terminal sedation were included in this analysis.
  • CONCLUSIONS: Sedated, terminal cancer patients usually live about one day.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961628.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Levine MN, Deitchman D, Julian J, Liebman H, Escalante C, O'Brien MC, Ramirez L, Weise-Kelly L, Solymoss S: A randomized phase II trial of a new anticoagulant, apixaban, in metastatic cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e20514

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized phase II trial of a new anticoagulant, apixaban, in metastatic cancer.
  • : e20514 Background: Cancer patients receiving chemotherapy, biologic, and molecular targeted therapies are at increased risk of venous thromboembolism (VTE).
  • We wanted to assess the feasibility of A in cancer.
  • METHODS: In a randomized phase II trial, patients with metastatic cancer on 1<sup>st</sup> or 2<sup>nd</sup> line chemotherapy received study drug once daily for 12 weeks; either 5, 10 or 20 mg of A, or placebo.
  • The numbers of patients with events were: Conclusions: Apixiban was well tolerated in patients with advanced cancer on chemotherapy.
  • These results support further study of A in phase III trials for VTE prevention in cancer patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960918.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Saunders M, Anthoney A, Coffey M, Mettinger K, Thompson B, Melcher A, Nutting CM, Harrington K: Results of a phase II study to evaluate the biological effects of intratumoral (ITu) reolysin in combination with low dose radiotherapy (RT) in patients (Pts) with advanced cancers. J Clin Oncol; 2009 May 20;27(15_suppl):e14514

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of a phase II study to evaluate the biological effects of intratumoral (ITu) reolysin in combination with low dose radiotherapy (RT) in patients (Pts) with advanced cancers.
  • : e14514 Background: Reolysin, a wild type reovirus serotype 3 Dearing strain, replicates preferentially in Ras-activated cancer cells.
  • Pts with ECOG performance status ≤2, with refractory advanced or metastatic cancers were eligible.
  • RESULTS: 16 heavily pre-treated pts (9 male, median age 66 yrs, ECOG 0:4pts; 1:12pts) with advanced cancer: melanoma (5), colorectal (4), gastric (1), ovarian (1), pancreas (1), lung (1), cholangiocarcinoma (1), sinus (1), and thyroid (1) were enrolled since Dec 2006.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963520.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Quevedo F, Ashdown ML, Suman VJ, Robinson A, Kottschade LA, Kaur JS, Creagan ET, McWilliams RR, Markovic SN: Possible therapeutic reversal of immune suppression in patients with metastatic melanoma by timed delivery of temozolomide chemotherapy: A pilot study. J Clin Oncol; 2009 May 20;27(15_suppl):e20013

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e20013 Background: Recent evidence suggests that patients with advanced cancer exhibit an underlying anti-tumor immune response that is continuously attenuated by regulatory T cells (Treg).
  • CONCLUSIONS: These data suggest that patient clinical outcome may be dependent on the timing of therapy relative to an individual patient's immune response cycle and outline the dynamic equilibrium of systemic immune homeostasis in patients with advanced melanoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962562.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Lindsay CR, Chan E, Evans TR, Campbell S, Bell P, Stephens AW, Franke A, Poondru S, Rothenberg ML, Puzanov I: Phase I dose escalation study of continuous oral dosing of OSI-906, an insulin like growth factor-1 receptor (IGF-1R) tyrosine kinase inhibitor, in patients with advanced solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):2559

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I dose escalation study of continuous oral dosing of OSI-906, an insulin like growth factor-1 receptor (IGF-1R) tyrosine kinase inhibitor, in patients with advanced solid tumors.
  • METHODS: Patients with advanced cancer entered escalating dose cohorts of OSI-906.
  • Stable disease > 12 weeks was seen in 7/20 pts (range 12-34 weeks), including 1 pt each with thymic (27 w), adrenocortical (28w), and colorectal (34w) cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961869.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. D'Olimpio JT, Chasen MR, Sharma R, Diego M, Gullo V, MacDonald N: Phase II study of AVR118 in the management of cancer related anorexia/cachexia. J Clin Oncol; 2009 May 20;27(15_suppl):e20631

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of AVR118 in the management of cancer related anorexia/cachexia.
  • In a previous study in patients with advanced HIV-AIDS, an improvement in appetite, strength and alertness was noted.
  • OBJECTIVE: To determine the effect of AVR118 on appetite, early satiety and nutritional intake in patients with advanced cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961581.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Elsayem AF, Hui D, Li Z, Flores M, Atkinson WA 4th, Bruera E: Acute palliative care unit in a comprehensive cancer center (CCC): Financial and clinical outcomes. J Clin Oncol; 2009 May 20;27(15_suppl):e20518

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute palliative care unit in a comprehensive cancer center (CCC): Financial and clinical outcomes.
  • : e20518 Background: Acute palliative care units (APCU) in CCCs improves symptom control for advanced cancer patients and supports their families.
  • However, these services are not available in the majority of cancer centers.
  • Further research is needed to investigate possible reasons for lack of APCU in cancer centers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960912.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Li J, Zhou X, Liu Q, Wang Z, Li Y, Li Y: The correlation between the expression of ABH and Lewis A histo-blood group antigens and the biological behavior of primary pulmonary adenocarcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e19066

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • While in cancer tissue, such expression was absent.
  • And the absent expression was statistically higher in tumor with metastasis than in without metastasis (P=0.036),higher in N<sub>2</sub> than in N<sub>1</sub> group, higher in secondary tumor in than primary focus(P=0.008).There was significantly statistical difference on the absent expression rates among normal pulmonary tissue, primary tumor and metastatic tumor (P<0.001), and having a tendency of increased absence rate.
  • Concerning Lewis A expression, the significant difference was found in Stage I,II and III+IV cancers (P=0.001), while the positive expression rate in advanced cancer (StageII+III+IV) was remarkably higher than in early cancer (Stage I) .

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962141.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Kim KB, Davies MA, Papadopoulos NE, Bedikian AY, Hwu W, Woodard K, Washington EW, Dancey JE, Wright J, Hwu P: Phase I/II study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma. J Clin Oncol; 2009 May 20;27(15_suppl):9026

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 9026 Background: Inhibition of Signal transduction pathways at multiple levels may be a more effective therapeutic cancer strategy for advanced cancer patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962093.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Gamucci T, Narducci F, Sperduti I, Mentuccia L, Trapasso T, Magnolfi E, Grande R, Cianci G, Gemma D, Trombetta G: Evaluation of the Edmonton Symptoms Assesment Scale (ESAS) symptoms improvement (SI) assessment as a prognostic factor for survival in advanced cancer patients (pts) undergoing palliative care (PC): An observational prospective study. J Clin Oncol; 2009 May 20;27(15_suppl):9591

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of the Edmonton Symptoms Assesment Scale (ESAS) symptoms improvement (SI) assessment as a prognostic factor for survival in advanced cancer patients (pts) undergoing palliative care (PC): An observational prospective study.
  • To this purpose, an observational prospective study in advanced cancer pts previously treated with anti-cancer treatments and now undergoing only PC was conducted.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963728.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Hlubocky FJ, Larson E, Ratain MJ, Sachs G, Daugherty CK: Cognitive function (CF) and prognostic information understanding in advanced cancer patients (ACP). J Clin Oncol; 2009 May 20;27(15_suppl):9516

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cognitive function (CF) and prognostic information understanding in advanced cancer patients (ACP).
  • : 9516 Background: The role of advanced cancer patients' (ACP) cognitive function (CF) and its relationship to understanding of a terminal prognosis has never been formally evaluated.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964487.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Phelps AC, Maciejewski PK, Nilsson M, Balboni TA, Wright AA, Trice E, Block SD, Prigerson HG: Coping with cancer: Associations between coping methods and use of intensive life-prolonging care near death. J Clin Oncol; 2009 May 20;27(15_suppl):9575

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coping with cancer: Associations between coping methods and use of intensive life-prolonging care near death.
  • : 9575 Background: Cancer patients cope with advanced illness in a variety of ways, including relying on their religious beliefs.
  • We sought to determine how patient coping mechanisms affect the use of intensive life-prolonging EOL care among advanced cancer patients.
  • METHODS: The Coping with Cancer Study is a US multi-site, prospective, longitudinal cohort of 345 advanced cancer patients enrolled January, 2003 -August, 2007.
  • CONCLUSIONS: The manner in which patients cope with advanced cancer predicts receipt of intensive life-prolonging care at the EOL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963713.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Nallapareddy S, Gustafson D, Leong S, Messersmith W, Arnott J, Eckhardt SG, Sidor C, Camidge DR: A single-center, open-label, dose escalation, safety, and pharmacokinetic study of ENMD-1198 administered orally to patients (pts) with advanced cancer. J Clin Oncol; 2009 May 20;27(15_suppl):3562

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A single-center, open-label, dose escalation, safety, and pharmacokinetic study of ENMD-1198 administered orally to patients (pts) with advanced cancer.
  • METHODS: Eligible pts had advanced cancer for which no effective therapy exists that is either evaluable by RECIST criteria or tumor markers that could be monitored for clinical benefit.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961688.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Vaklavas C, Tsimberidou AM, Moulder S, Ng C, Naing A, Daring S, Bedikian A, Uehara C, Kurzrock R: A phase I study dose escalation clinical study of hepatic intraarterial cisplatin, combination systemic intravenous liposomal doxorubicin in patients advanced cancer dominant liver involvement. J Clin Oncol; 2009 May 20;27(15_suppl):e13512

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I study dose escalation clinical study of hepatic intraarterial cisplatin, combination systemic intravenous liposomal doxorubicin in patients advanced cancer dominant liver involvement.
  • We conducted a phase I study of hepatic arterial infusion (HAI) and intravenous (IV) chemotherapy in patients with advanced cancer and dominant liver involvement.
  • Diagnoses were breast cancer (n=11), colorectal cancer (n= 8), ocular melanoma (n=4), and other (n=7).
  • Of the 11 patients with breast cancer, 3 had a PR and 4 had SD.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961306.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Effects of massage on pain in cancer care are not sustained. Nurs Stand; 2008 Nov 05;23(9):17

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of massage on pain in cancer care are not sustained.
  • : Researchers in the United States evaluated the efficacy of massage for decreasing pain and symptom distress, and improving quality of life among people with advanced cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28019584.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


67. Bush SH, Parsons HA, Palmer JL, Chacko R, Li Z, Scott C, Bruera E: Single- versus multiple-item assessment of quality of life in patients with advanced cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e20528

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Single- versus multiple-item assessment of quality of life in patients with advanced cancer.
  • : e20528 Background: The main objective of palliative cancer care is to improve quality of life (QOL).
  • We assessed the performance of the Edmonton Symptom Assessment System 'feeling of well-being' item (ESAS WB) using the Functional Assessment of Cancer Therapy - General (FACT-G) instrument as a gold standard.
  • METHODS: After obtaining IRB approval, we reviewed the data from 213 advanced cancer patients who had participated in six studies from March 2006 to June 2008 and determined the level of association between baseline ESAS WB and FACT-G total score and subscale domains (Physical (Pwb), Social/Family (Swb), Emotional (Ewb), and Functional (Fwb) Well-Being) and also the 9 ESAS symptom intensity scores using Spearman correlation coefficients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961001.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Balboni TA, Paulk ME, Balboni MJ, Trice ED, Wright AA, Phelps AC, Block SD, Prigerson HG: Spiritual support of patients with advanced illness and associations with end-of-life care and quality of death. J Clin Oncol; 2009 May 20;27(15_suppl):9514

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spiritual support of patients with advanced illness and associations with end-of-life care and quality of death.
  • : 9514 Background: Little is known about whether spiritual support is associated with advanced cancer patients' medical care and quality of death (QoD) at the end of life (EoL).
  • METHODS: Coping with Cancer is an NCI/NIMH-funded, prospective, longitudinal, multi-institutional study of advanced, incurable cancer patients conducted from September 2002-August 2008.
  • CONCLUSIONS: Support of advanced cancer patients' spiritual needs by the medical care team is associated with increased receipt of hospice care and improved patient QoD.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964485.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Pourchet S, Montheil V, Ropert S, Alexandre J, Goldwasser F, Durand JP: Validation of a scoring system to improve life expectancy prediction in advanced cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):e20507

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Validation of a scoring system to improve life expectancy prediction in advanced cancer patients.
  • : e20507 Background: Oncologists accurately estimates survival in 20% of cases for advanced cancer patients (J Clin Oncol 2005 23:6240-48), leading to prescribe chemotherapy until last weeks of life.
  • CONCLUSIONS: This score could help "go/no go" decisions of chemotherapy in advanced cancer patients and reduces errors of life expectancy prediction from 80% to 22%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960943.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Rose PG, Drake R, Braly PS, Bell MC, Wenham RM, Hines JH, Alvarez-Secord A, Soltes-Rak E, Childs BH, Herzog TJ: Preliminary results of a phase II study of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube. J Clin Oncol; 2009 May 20;27(15_suppl):5546

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preliminary results of a phase II study of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube.
  • : 5546 Background: Objectives are to estimate efficacy and safety of a novel taxane/platinum chemotherapy doublet in combination with bevacizumab (B), as first-line treatment of advanced cancer of the ovary, peritoneum or fallopian tube (FT), after initial debulking surgery.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962510.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Kim Y, Lee J, Choi W, Park J, Kim H, Lee S, Kim D, Lee J, Bang Y, Heo DS: Effect of interval between diagnosis of advanced cancer and cessation of active anti-cancer treatment on survival in terminally ill cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):e20630

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of interval between diagnosis of advanced cancer and cessation of active anti-cancer treatment on survival in terminally ill cancer patients.
  • : e20630 Background: Although various prognostic factors have been proposed to predict survival in terminally ill cancer patients, accurate prognostication is still a challenging task for oncologists.
  • The objective of this study was to evaluate whether the time interval between diagnosis of advanced cancer and cessation of active anti-cancer treatment (ATP; active treatment period) can predict survival in terminally ill cancer patients.
  • METHODS: We prospectively evaluated 79 patients with advanced (recurrent or metastatic) cancer who were determined as terminal stage, namely cessation of active anti-cancer treatment and transition to palliative care, by attending oncologists.
  • Median overall survival after being diagnosed with advanced cancer was 11.6 months (95% confidence interval (CI), 8.02-15.18), and survival after being determined as terminal stage was 1.9 months (95% CI, 1.38-2.42).
  • On multivariate analysis, short ATP, non-colorectal cancer, fatigue, and Karnofsky performance status less than 50 were significantly associated with a poor prognosis.
  • CONCLUSIONS: Our study suggests that ATP is an independent prognostic factor for survival in terminally ill cancer patients who cannot receive active anti-cancer treatment anymore.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961582.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Underhill C, Millward M, Lobb S, McBurnie J, Meech S, Gomez-Navarro J, Readett D, Bulanhagui CA: Phase I dose escalation trial of tremelimumab (CP-675,206) administered in combination with PF-3512676 in patients with melanoma or other advanced cancers. J Clin Oncol; 2009 May 20;27(15_suppl):3046

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I dose escalation trial of tremelimumab (CP-675,206) administered in combination with PF-3512676 in patients with melanoma or other advanced cancers.
  • : 3046 Background: Tremelimumab, a fully human monoclonal antibody specific for cytotoxic T-lymphocyte antigen 4 (CTLA4), and PF-3512676, an oligodeoxynucleotide toll-like receptor 9 agonist, are both novel, targeted immune modulators that can elicit durable antitumor responses in patients with advanced cancer.
  • METHODS: Eligibility criteria included advanced melanoma or other advanced cancer, ECOG performance status of 0 or 1, and no history of autoimmune disease.
  • CONCLUSIONS: At dose levels tested to date, the combination of tremelimumab and PF-3512676 has been tolerable and showed evidence of antitumor activity in patients with advanced melanoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961977.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Wright AA, Mack JW, Trice ED, Balboni TA, Block SD, Prigerson HG: Personalized end-of-life care: Associations between patient preferences and treatment intensity near death. J Clin Oncol; 2009 May 20;27(15_suppl):6516

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Coping with Cancer is an NCI/NIMH-funded, multi-site prospective, longitudinal cohort study of patients with advanced cancer, conducted from September 2002-February 2008.
  • Analyses were adjusted for significant confounds; i.e., socio-demographics, cancer type, patient denial, EOL discussion, do-not resuscitate (DNR) order, and treatment center.
  • CONCLUSIONS: Advanced cancer patients' treatment preferences may play a more important role in determining the intensity of medical care at the EOL than previously recognized.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964022.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Kwak EL, Camidge DR, Clark J, Shapiro GI, Maki RG, Ratain MJ, Solomon B, Bang Y, Ou S, Salgia R: Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066. J Clin Oncol; 2009 May 20;27(15_suppl):3509

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A Phase 1 dose-escalation trial evaluating PF as an oral single agent was conducted to investigate safety, PK and PD in patients (pts) with advanced cancer (excluding leukemias).
  • Pts with advanced cancer were enrolled in the study.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961297.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Rand K, Cripe LD, Monahan P, Tong Y, Schmidt K, Rawl S: Relationships among patient-level factors, religious coping, use of complementary and alternative medicine, and psychological outcomes in men with advanced cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e20652

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationships among patient-level factors, religious coping, use of complementary and alternative medicine, and psychological outcomes in men with advanced cancer.
  • : e20652 Background: Religious coping and complementary and alternative medicine (CAM) are two resources frequently used to manage distress associated with advanced cancer.
  • However, the relationships among these coping strategies and psychological outcomes in men with advanced cancer are not well studied.
  • METHODS: 81 men with advanced cancer were recruited from oncology clinics for this cross-sectional study.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961629.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Carducci MA, Armstrong DK, Collins C, Wang T, Schaefer S, Ermisch S, Musib LC, Nicol S, Thornton DE, Zhang Z: Phase I study of enzastaurin (ENZ) and bevacizumab (BV) in patients with advanced cancer: Safety, pharmacokinetics (PK), and response assessment. J Clin Oncol; 2009 May 20;27(15_suppl):3517

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of enzastaurin (ENZ) and bevacizumab (BV) in patients with advanced cancer: Safety, pharmacokinetics (PK), and response assessment.
  • METHODS: Eligible patients (pts) had advanced cancer, adequate organ function and no co-morbidities for increased risk of drug-related toxicities.
  • RESULTS: 43 pts (21 with ovarian cancer) are evaluable for toxicity.
  • CONCLUSIONS: The addition of ENZ to BV in any of the currently approved BV dosing schedules is well tolerated and clinically active in advanced cancer pts.
  • The combination of ENZ / BV demonstrates encouraging activity, specifically in our population of ovarian cancer pts.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961299.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Lewis L, Frank R, Dandamudi UB, Gallagher J, Zhao L, Woo M, Hirawat S, Shapiro GI: Influence of food on the pharmacokinetics (PK) of panobinostat (LBH589), an orally active histone deacetylase inhibitor, in patients with advanced cancer. J Clin Oncol; 2009 May 20;27(15_suppl):2550

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of food on the pharmacokinetics (PK) of panobinostat (LBH589), an orally active histone deacetylase inhibitor, in patients with advanced cancer.
  • : 2550 Background: The effect of food on the bioavailability and PK of panobinostat (PAN) are of considerable importance in allowing appropriate dosing of chronic oral cancer therapy.
  • METHODS: Patients (pts) with advanced cancer received 20 mg PAN twice a week of a 21-day cycle and were randomized to receive 1 of 6 treatment sequences where PAN PK was evaluated weekly under fasting, high fat and normal breakfast.
  • CONCLUSIONS: Since the overall extent of absorption and variability was not changed due to food, PAN administration with or without food is unlikely to significantly impact systemic PAN exposure in cancer patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961876.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Schmidt K, Monahan P, Tong Y, Rawl S, Rand K, Cripe LD: Coping styles and psychological outcomes in men with advanced cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e20521

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coping styles and psychological outcomes in men with advanced cancer.
  • : e20521 Background: The psychological outcomes of men with advanced cancer may vary based upon their appraisal and response to the threat of cancer.
  • Coping styles in other illnesses are influenced by gender and stage of disease, but little is known specifically about men with advanced cancer.
  • METHODS: We recruited 81 men with advanced cancer to complete surveys assessing coping (Mini-MAC), post-traumatic growth (PTGI), and psychological outcomes (Hospital Anxiety and Depression Scale).
  • CONCLUSIONS: As expected men with advanced cancer report anxiety and depression.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961013.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Valenzuela B, Nalda R, Duart M, Escudero V, Perez-Ruixo J, Martinez-Navarro E, Rebollo J, Gonzalez R, Brugarolas A: UGT1A1,A7 and A9 genotyping and pharmacokinetics of irinotecan-containing chemotherapy in patients with advanced cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e14563

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] UGT1A1,A7 and A9 genotyping and pharmacokinetics of irinotecan-containing chemotherapy in patients with advanced cancer.
  • : e14563 Background: To the best of our knowledge only one previous report in asian lung cancer patients (pts) assesed UGT1A1, A7 and A9 genotypes along with irinotecan pharmacokinetics (Han et al.
  • We set out to evaluate UGT1A1, A7 and A9 genotypes in caucasian cancer patients and their relationship with both irinotecan toxicity and irinotecan pharmacokinetics.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963692.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Daugherty C, Kass NE, Roter D, Larson S, Sugarman J, Kasza K, Ratain MJ, Hlubocky FJ: A study of physician investigator (PI) disclosure of alternatives of care and prognostic information to advanced cancer patients (ACP) enrolling in phase I trials. J Clin Oncol; 2009 May 20;27(15_suppl):6508

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A study of physician investigator (PI) disclosure of alternatives of care and prognostic information to advanced cancer patients (ACP) enrolling in phase I trials.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964011.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Hui D, Bruera E, Li Z, Palmer JL, de la Cruz M, Elsayem A: Utilization of antineoplastic therapy (ANT) in advanced cancer patients admitted to an acute palliative care unit (APCU) at a comprehensive cancer center. J Clin Oncol; 2009 May 20;27(15_suppl):9590

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utilization of antineoplastic therapy (ANT) in advanced cancer patients admitted to an acute palliative care unit (APCU) at a comprehensive cancer center.
  • : 9590 Background: Cancer patients admitted to a palliative care unit generally have a poor prognosis.
  • Demographics, cancer diagnosis and ANTs utilization from day of hospitalization to discharge, and survival information were retrieved retrospectively.
  • RESULTS: 2604 cancer patients had the following characteristics: median age 59 (range 18-101), male 51%, hematologic malignancy 11%, median hospital stay 11 (Q1-Q3 8-17) days, median APCU stay 7 (Q1-Q3 4-10) days and median survival 22 days.
  • Multivariate logistic regression analysis ( Table ) revealed that younger age, cancer primaries and longer admissions were associated with ANT use.
  • ANT use was associated with younger age, specific cancer primaries, longer admissions, and no significant improvement in survival.
  • The APCU at our cancer center facilitates simultaneous care where patients access palliative care while on ANT.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963726.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. MacRae C, Richardson PG, Walker J, Grayzel DS, Demetri GD: Cardiovascular safety profile of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor: Results from two independent phase I trials in patients with advanced cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e14539

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiovascular safety profile of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor: Results from two independent phase I trials in patients with advanced cancer.
  • : e14539 Background: Heat shock protein 90 (Hsp90) is a protein chaperone that regulates the proper folding, stability, and function of multiple mutated and wild type signaling proteins that promote malignant phenotypes.
  • Since Hsp90 is a novel cancer target that is ubiquitously expressed in normal cells, a comprehensive evaluation of potential cardiac effects, including the risk of ventricular arrhythmia, was performed in two Phase I trials.
  • METHODS: ECG data were pooled and analyzed from 60 pts in two-open label Phase I trials of patients with advanced cancers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963557.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. de la Cruz M, Hui D, Parsons HA, Lynn P, Parker C, Urbauer D, Bruera E: Placebo and nocebo effects in randomized double-blind clinical trials for fatigue in advanced cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):9640

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Placebo and nocebo effects in randomized double-blind clinical trials for fatigue in advanced cancer patients.
  • : 9640 Background: We have previously reported significant placebo response in randomized controlled treatment trials for cancer related fatigue (CRF).
  • RESULTS: A total of 105 advanced cancer patients received placebo.
  • CONCLUSIONS: Nearly half of advanced cancer patients enrolled in the fatigue trials responded to placebo.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963922.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Roodhart JM, Langenberg MH, Vermaat JS, Lolkema MP, Witteveen PO, Voest EE: Correlation of release of endothelial (progenitor) cells after chemotherapy: Kinetics with response and survival. J Clin Oncol; 2009 May 20;27(15_suppl):11002

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 11002 Background: Recently we have shown that in preclinical models and in cancer patients certain types of chemotherapy can induce an acute release of progenitor cells (Shaked et al, Cancer Cell 2008).
  • METHODS: Patients with mainly advanced cancer treated with various types of MTD chemotherapy were included.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964053.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Moss AH, Lunney JR, Culp S, Auber M, Kurian S, Rogers J, Dower J, Abraham J: Prognostic significance of the "surprise" question in cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):9588

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of the "surprise" question in cancer patients.
  • : 9588 Background: In patients with advanced cancer, failure to accurately estimate and communicate prognoses can lead to overly aggressive care at the end of life with less attention to important palliative care issues such as pain and symptom management and patients' values and goals for care.
  • It has not been previously tested in cancer patients.
  • The purposes of this study were to determine the feasibility and outcomes of the use of the "surprise" question in a cancer center population.
  • METHODS: Between July and November 2007, oncologists prospectively classified consecutive breast, lung, and colon cancer patients being seen at the Mary Babb Randolph Cancer Center of West Virginia University into "Yes" and "No" groups based on the surprise question.
  • Patients were followed and their status at the end of one year-alive or dead-was determined along with patient demographics, type of cancer, and stage at presentation.
  • The surprise question 'No' response was more predictive of patient death than stage of cancer, cancer type, or age (hazard ratio 7.53, P value <.001).
  • CONCLUSIONS: We conclude that the surprise question is a simple, feasible, and effective tool to identify cancer patients with the worst prognoses who should receive the highest priority for palliative care interventions, particularly advance care planning.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963736.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Parsons HA, de La Cruz M, Delgado-Guay MO, Akitoye AE, Chacko R, Poulter V, Bruera E: Characteristics of patients who refuse medically appropriate do not resuscitate orders (DNR) upon admission to a palliative care (PC) unit in a comprehensive cancer center. J Clin Oncol; 2009 May 20;27(15_suppl):9589

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics of patients who refuse medically appropriate do not resuscitate orders (DNR) upon admission to a palliative care (PC) unit in a comprehensive cancer center.
  • : 9589 Background: Cardiopulmonary resuscitation (CPR) has limited benefit in advanced cancer patients (pts).
  • We conducted a retrospective study to determine the frequency of refusals of maDNR in a tertiary PC unit in a comprehensive cancer center, and characterize the differences between maDNR acceptors (A) and refusers (R).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963735.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Bjerregaard JK, Schønnemann KR, Jensen HA, Vestermark LW, Hansen TP, Pfeiffer P: Biweekly cetuximab and irinotecan as second-line therapy to patients with platinium-resistant gastroesophageal cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15624

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biweekly cetuximab and irinotecan as second-line therapy to patients with platinium-resistant gastroesophageal cancer.
  • : e15624 Background: There is no established 2<sup>nd</sup> line therapy for patients (pts) with advanced gastroesophageal (GE) cancer.
  • In 2004, the Danish government initiated a national health programme for pts with advanced cancer.
  • This programme has had a major impact on the management of cancer pts in Denmark and has accelerated the introduction and implementation of new therapies.
  • Inspired by the excellent results in colorectal cancer a combination of cetuximab and irinotecan (CetIri) was chosen for platinum-resistant GE cancer.
  • We report our preliminary experience with biweekly CetIri as 2<sup>nd</sup> line therapy in pts with GE cancer.
  • METHODS: All pts had histologically confirmed GE cancer (adeno- or squamous cell carcinoma) and all pts had previously received first line platinum based therapy.
  • CONCLUSIONS: Biweekly CetIri is a convenient and well-tolerated 2<sup>nd</sup> line regimen in pts with GE cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962695.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Scheusan R, Curescu S, Stanculeanu D, Curescu P: Low-dose methotrexate and cyclophosphamide in recurrent ovarian cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e16574

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-dose methotrexate and cyclophosphamide in recurrent ovarian cancer.
  • : e16574 Background: Ovarian cancer continues to be the leading cause of death secondary to gynecologic cancers among women.
  • Metronomic chemotherapy, chronic administration of chemotherapy at relatively low, minimally toxic doses on a frequent schedule with no prolonged drug-free breaks, is a potentially novel approach to the control of advanced cancer disease.
  • PURPOSE: to evaluate the efficacy and toxicity of metronomic chemotherapy using low dose methotrexate and cyclophosphamide in patients with refractory pretreated ovarian cancer.
  • CONCLUSIONS: Metronomic metotrexate-cyclophosphamide is minimally toxic and effective in heavily pretreated recurrent ovarian cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961511.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Halstead JC, Lim E, Venkateswaran RM, Charman SC, Goddard M, Ritchie AJ: Improved survival with VATS pleurectomy-decortication in advanced malignant mesothelioma. Eur J Surg Oncol; 2005 Apr;31(3):314-20
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved survival with VATS pleurectomy-decortication in advanced malignant mesothelioma.
  • AIMS: Malignant mesothelioma is increasing in incidence and no current therapy significantly prolongs survival.
  • We present the results of VATS debulking pleurectomy-decortication in advanced disease.
  • METHODS: A consecutive series of patients with suspected malignant mesothelioma underwent thoracoscopic assessment to determine the feasibility of decortication, where this was not possible a biopsy alone was taken.
  • CONCLUSION: VATS pleurectomy-decortication is feasible in the majority of cases and independently improves survival for patients with advanced malignant mesothelioma.
  • [MeSH-minor] Actuarial Analysis. Aged. Feasibility Studies. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Proportional Hazards Models. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15780570.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


90. de Arriba Méndez JJ: [Prognosis of survival in advanced cancer]. Rev Clin Esp; 2007 Jul-Aug;207(7):348-51

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognosis of survival in advanced cancer].
  • [Transliterated title] Pronóstico de supervivencia en el cáncer avanzado.
  • Accurate prognoses are important in the care of patients with advanced cancer to assist clinicians in their decision making, and to help patients set their goals and priorities.
  • Several studies have demonstrated that doctors are inaccurate and overly optimistic when predicting the survival of patients with advanced and terminal cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17662201.001).
  • [ISSN] 0014-2565
  • [Journal-full-title] Revista clínica española
  • [ISO-abbreviation] Rev Clin Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


91. Kawamura S, Nakamura T, Oya T, Ishizawa S, Sakai Y, Tanaka T, Saito S, Fukuoka J: Advanced malignant solitary fibrous tumor in pelvis responding to radiation therapy. Pathol Int; 2007 Apr;57(4):213-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced malignant solitary fibrous tumor in pelvis responding to radiation therapy.
  • Solitary fibrous tumor (SFT) is a rare spindle cell neoplasm that is benign in most cases.
  • Herein is reported a case of a 74-year-old woman with a giant malignant SFT in the pelvis.
  • Along with massive invasion to adjacent organs and multiple lung metastases detected on radiography, biopsy from the tumor through the vaginal wall showed malignant looking spindle-cell neoplasm with increased cellularity, areas of necrosis, and high mitotic activity (5/10 high-power fields).
  • Based on pathological features and clinical presentation, diagnosis of malignant SFT was made.
  • This is the first report related to therapeutic remarks on advanced malignant SFT.
  • [MeSH-minor] Aged. Disease Progression. Female. Humans. Magnetic Resonance Imaging. Neoplasm Metastasis / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17316417.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


92. Chang CH, Shu MT, Lee JC, Leu YS, Chen YC, Lee KS: Treatments and outcomes of malignant tumors of external auditory canal. Am J Otolaryngol; 2009 Jan-Feb;30(1):44-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatments and outcomes of malignant tumors of external auditory canal.
  • PURPOSE: Primary cancer of the external auditory canal (EAC) is a rare disease with poor prognosis.
  • The purpose of this study is to evaluate the treatment modalities and outcomes for malignant tumors of EAC at our institute, comparing with other studies.
  • METHODS: We retrospectively reviewed the patients treated for primary cancer of EAC between 1991 and 2002 at our hospital, which is a tertiary referral center.
  • CONCLUSIONS: Patients with early-stage cancer can benefit from less aggressive surgical interventions without significant morbidity or mortality.
  • However, patients with advanced cancer had high recurrence rate despite of adjuvant radiotherapy, suggesting more aggressive surgical approach for complete resection was necessary.
  • [MeSH-major] Ear Canal / pathology. Ear Neoplasms / mortality. Ear Neoplasms / therapy. Neoplasm Recurrence, Local / mortality
  • [MeSH-minor] Adult. Aged. Carcinoma, Adenoid Cystic / mortality. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Adenoid Cystic / therapy. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / therapy. Cohort Studies. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Otologic Surgical Procedures / methods. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate. Taiwan

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19027512.001).
  • [ISSN] 1532-818X
  • [Journal-full-title] American journal of otolaryngology
  • [ISO-abbreviation] Am J Otolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Shah BK, Qamruzzaman Y, Serban K, Hire E, Ying SC: First case report of locally advanced malignant nodular hidradenoma of the scrotum. Onkologie; 2010;33(12):701-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] First case report of locally advanced malignant nodular hidradenoma of the scrotum.
  • BACKGROUND: Malignant nodular hidradenoma (MNH) is a malignant tumor of the eccrine glands, and most commonly involves the head, trunk, and extremities.
  • CASE REPORT: We describe the case of a 30-year-old African American man who was diagnosed with locally advanced MNH of the scrotum and treated with surgery.
  • Surgery alone may be sufficient for the treatment of localized or locally advanced MNH.
  • [MeSH-minor] Adult. Follow-Up Studies. Humans. Lymph Node Excision. Lymph Nodes / pathology. Lymphatic Metastasis / pathology. Male. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 S. Karger AG, Basel.
  • (PMID = 21124043.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


94. Banhiran W, Casiano RR: Endoscopic sinus surgery for benign and malignant nasal and sinus neoplasm. Curr Opin Otolaryngol Head Neck Surg; 2005 Feb;13(1):50-4
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic sinus surgery for benign and malignant nasal and sinus neoplasm.
  • With increased skill with endoscopic surgical technique, advanced technologies such as intraoperative imaging systems, and a better understanding of the complex anatomy of the paranasal sinuses and surrounding vital structures, many otolaryngologists have increasingly applied their expertise in endoscopic sinus surgery to the resection of nasal and sinus neoplasms.
  • There have been a few recent reports supporting endoscopic removal of malignant neoplasms as well.

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15654216.001).
  • [ISSN] 1068-9508
  • [Journal-full-title] Current opinion in otolaryngology & head and neck surgery
  • [ISO-abbreviation] Curr Opin Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 43
  •  go-up   go-down


95. Preś K, Pośpiech L, Krecicki T, Nadolska B, Kubacka M, Zatoński T, Jabłonka A, Piechnik-Resler D, Jankowska-Konsur A: [Malignant neoplasm of nose and paranasal sinuses in Lower Silesia in years 1992-2001]. Wiad Lek; 2006;59(11-12):797-800
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant neoplasm of nose and paranasal sinuses in Lower Silesia in years 1992-2001].
  • Malignant neoplasms of the nose and paranasal sinuses occur rarely but due to late diagnosis and poor treatment effects still remain a serious problem.
  • MATERIAL AND METHODS: In the years 1992-2001 in Lower Silesia region there were 182 patients treated for malignant nose and paranasal sinus tumors.
  • CONCLUSIONS: Unsatisfactory results of treatment are an effect of a high advanced stage of the tumor while diagnosed.
  • [MeSH-minor] Disease-Free Survival. Female. Humans. Lymphatic Metastasis. Male. Neoplasm Staging / classification. Nose. Poland / epidemiology. Radiotherapy, Adjuvant. Retrospective Studies. Sex Distribution. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17427494.001).
  • [ISSN] 0043-5147
  • [Journal-full-title] Wiadomości lekarskie (Warsaw, Poland : 1960)
  • [ISO-abbreviation] Wiad. Lek.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


96. O'Connor R, O'Leary M, Ballot J, Collins CD, Kinsella P, Mager DE, Arnold RD, O'Driscoll L, Larkin A, Kennedy S, Fennelly D, Clynes M, Crown J: A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer. Cancer Chemother Pharmacol; 2007 Jan;59(1):79-87
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer.
  • PURPOSE: Multi-drug resistance mediated by ATP-binding cassette trans-membrane protein pumps is an important cause of cancer treatment failure.
  • Sulindac has been shown to be a competitive substrate for the clinically important resistance protein, multi-drug resistance protein-1 (MRP-1), and thus might enhance the anti-cancer activity of substrate chemotherapeutic agents, e.g. anthracyclines.
  • METHODS: We conducted a dose-escalating, single arm, prospective, open label, non-randomised phase I trial of epirubicin (75 mg/m(2)) in combination with escalating oral doses of sulindac (0-800 mg) in patients with advanced cancer to identify an appropriate dose of sulindac to use in future resistance studies.
  • Dose-limiting toxicity was observed in two patients at 800 mg sulindac (1 renal impairment, 1 fatal haemoptysis in a patient with advanced lung cancer), and sulindac 600 mg was deemed to be the maximum tolerated dose.
  • Among 15 patients with evaluable tumour, two partial responses were seen (malignant melanoma and breast cancer).
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Creatinine / blood. Dose-Response Relationship, Drug. Drug Resistance, Multiple / drug effects. Drug Resistance, Neoplasm / drug effects. Female. Humans. Immunohistochemistry. Male. Middle Aged. Myocardium / metabolism. Platelet Count. Prospective Studies. Troponin / metabolism

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16642371.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Antibiotics, Antineoplastic; 0 / P-Glycoprotein; 0 / Troponin; 184SNS8VUH / Sulindac; 3Z8479ZZ5X / Epirubicin; AYI8EX34EU / Creatinine
  •  go-up   go-down


97. Aryana A, Esterbrooks DJ, Morris PC: Nonbacterial thrombotic endocarditis with recurrent embolic events as manifestation of ovarian neoplasm. J Gen Intern Med; 2006 Dec;21(12):C12-5
MedlinePlus Health Information. consumer health - Pulmonary Embolism.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nonbacterial thrombotic endocarditis with recurrent embolic events as manifestation of ovarian neoplasm.
  • This is a rare condition often associated with hypercoagulable states or advanced malignancy such as adenocarcinomas, characterized by cardiac vegetations along valvular coaptation lines without destruction of leaflets.
  • In our patient, we diagnosed an ovarian clear cell adenocarcinoma, a malignant disorder that has been rarely reported in association with NBTE.
  • When confronted with findings of NBTE without a clear etiology, an occult neoplasm must be excluded.


98. Lugović L, Situm M, Kos L: Malignant melanoma--future prospects. Acta Dermatovenerol Croat; 2005;13(1):36-43
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant melanoma--future prospects.
  • As the incidence and already high mortality rates of malignant melanoma have been steadily increasing in recent decades, the early detection and excision of malignant melanoma have imposed as the most important task.
  • Staging of malignant melanoma is determined according to the level of invasion (Clark level) and vertical thickness (Breslow scale).
  • Besides operative therapy, which is the only effective treatment for malignant melanoma, postoperative adjuvant chemotherapy, immunotherapy, radiotherapy, and biologic therapy also are of great importance.
  • In recent years, immunologic strategies including tumor vaccine and adjuvant therapy with interferon-alfa have been attempted to improve survival of patients with more advanced malignant melanoma.
  • Numerous chemotherapeutic agents have shown activity in the treatment of metastatic malignant melanoma, such as dacarbazine (dimethyl triazene imidazole carboxamide); other agents have been used, however, with less success.
  • However, a very modest effect was recorded in advanced malignant melanoma.
  • There are many experimental trials using combined therapy for malignant melanoma, including chemotherapy (dimethyl triazene imidazole carboxamide) and biologic therapy (interleukin (IL)-2, interferon (IFN)-gamma, IFN-alfa).
  • The results obtained open particularly interesting prospects in the field of malignant melanoma with high relevance for its development and progression.
  • [MeSH-minor] Antigens, Neoplasm. Cancer Vaccines. Cyclin-Dependent Kinase 4. Cyclin-Dependent Kinases / genetics. Genetic Therapy. Humans. Immunotherapy. Metalloproteases / metabolism. Proto-Oncogene Proteins / genetics. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15788145.001).
  • [ISSN] 1330-027X
  • [Journal-full-title] Acta dermatovenerologica Croatica : ADC
  • [ISO-abbreviation] Acta Dermatovenerol Croat
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Croatia
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Cancer Vaccines; 0 / Proto-Oncogene Proteins; EC 2.7.11.22 / CDK4 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinase 4; EC 2.7.11.22 / Cyclin-Dependent Kinases; EC 3.4.- / Metalloproteases
  • [Number-of-references] 40
  •  go-up   go-down


99. Tenorio-González F: [Ethics and palliative care in patients with advanced cancer]. Cir Cir; 2005 Nov-Dec;73(6):495-500
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ethics and palliative care in patients with advanced cancer].
  • [Transliterated title] Etica y cuidados paliativos en el enfermo con cáncer avanzado.
  • Recent research in both the biology of cancer and the treatment of patients has increased the life expectancy of cancer patients with recurrence and who have a longer survival rate.
  • Cancer is no longer considered a lethal but a chronic disease.
  • The American Cancer Society reported in 1992 that in the U.S. more than 8 million people survived between 4 and 5 years.
  • This produces both an ethical and medical challenge for treatment of cancer patients.
  • This paper reviews the actual criteria for palliative care: treatment for pain and the ethical and psychological treatment of advanced cancer patients and their families.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16454965.001).
  • [ISSN] 0009-7411
  • [Journal-full-title] Cirugía y cirujanos
  • [ISO-abbreviation] Cir Cir
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


100. Yamamoto Y, Goto M, Okamoto T, Tomita I, Murayama A, Sawa M, Noguchi Y, Hoshikawa Y, Shimizu A: [Chemotherapy-naïve advanced malignant fibrohistiocytoma presenting IVC syndrome case report]. Gan To Kagaku Ryoho; 2010 Feb;37(2):355-7
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chemotherapy-naïve advanced malignant fibrohistiocytoma presenting IVC syndrome case report].
  • A diagnosis of malignant fibrohistiocytoma was made by pathological examination of biopsied specimens at exploratory laparotomy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Doxorubicin / therapeutic use. Histiocytoma, Malignant Fibrous / complications. Histiocytoma, Malignant Fibrous / drug therapy. Ifosfamide / therapeutic use. Superior Vena Cava Syndrome / etiology. Vena Cava, Inferior / pathology
  • [MeSH-minor] Aged. Biopsy. Humans. Male. Neoplasm Staging. Tomography, X-Ray Computed

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20154502.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down






Advertisement